登录新浪财经APP 搜索【信披】查看更多考评等级 北京阳光诺和药物研究股份有限公司 关于召开2025年第五次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 股东会召开日期：2025年12月12日 2025年第五次临时股东会 召开日期时间：2025年12月12日 14点30分 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025年12月12日 证券代码：688621 证券简称：阳光诺和 公告编号：2025-106 至2025年12月12日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股东会召开当日的交易时间 段，即9:15-9:25，9:30-11:30，13:00-15:00；通过互联网投票平台的投票时间为股东会召开当日的9:15- 15:00。 （六）融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投票，应按照《上海证券交易 所科创板上市公司自律监管指引第1号 一 规 ...

来源：瑞恩资本RyanbenCapital 中国企业赴香港上市，需要取得中国证监会的备案通知书。根据港交所上市规则，中国企业需在上市聆 讯审批日期至少4个营业日之前提交"备案通知书"。只有通过港交所的上市聆讯，企业才可以在港交所 挂牌上市。 本周(2025年11月17日至11月21日)中国证监会国际司共对9家企业(全部在香港上市)出具境外发行上市备 案补充材料要求，具体如下：华勤技术、欢创科技、锐明技术、瘦西湖、武汉聚芯、岚图汽车、麦科奥 特。 华勤技术 四、请说明发行人及下属公司经营范围涉及广告业务的情况，是否实际开展广告业务及具体运营情况。 五、请说明国信资本、青岛国投、青岛微电子的国资管序办理进展。 六、请说明本次拟参与"全流通"股东所持股份是否存在质押、冻结或其他权利瑕疵的情形。 请你公司补充说明以下事项，请律师核查并出具明确的法律意见： 一、请说明实际控制人支配的股东持有发行人的股份存在质押的具体情况，并结合偿债能力等情况说明 本次发行完成前后，股份质押情况是否可能导致控制权发生变化，是否构成《境内企业境外发行证券和 上市管理试行办法》第八条规定的境外发行上市禁止性情形。 二、请按照《监管规则适用指 ...

工信部启动卫星物联网业务商用试验 登录新浪财经APP 搜索【信披】查看更多考评等级 《科创板日报》11月24日讯，今日科创板早报主要内容有：工信部启动卫星物联网业务商用试验；今年 我国低空经济市场规模预计将达1.5万亿元；华为发布Flex:ai AI容器技术；长鑫存储发布DDR5内存新 品，最高速率达8000Mbps；摩尔线程即将登陆科创板，今日启动申购。 《科创板日报》主播小K为您播报。 【市场动态】 美国政府据称正考虑允许英伟达对华出售H200芯片 根据相关消息，特朗普政府正考虑批准向中国出口美国芯片制造商英伟达的H200人工智能芯片。报道 援引知情人士消息称，负责监管美国出口管制的美国商务部正就改变对华出口限制一事进行审查，并称 相关计划可能会发生变动。报道称，美国商务部暂未对此作出回应，英伟达尚未就此直接置评。 华为发布Flex:ai AI容器技术 实现单卡同时承载多个AI工作负载 华为近日发布Flex:ai AI容器软件，通过算力切分技术，将单张GPU/NPU算力卡切分为多份虚拟算力单 元，切分粒度精准至10%，实现了单卡同时承载多个AI工作负载，并可聚合集群内各节点的空闲XPU算 力聚合形成"共享 ...

Core Viewpoint - The company is currently involved in a significant legal dispute with Hunan Hengsheng Pharmaceutical Co., Ltd., with ongoing appeals and potential financial implications for the company [2][3][5]. Summary by Sections Legal Proceedings - The case is in the second instance of litigation, which has been filed but not yet heard [2]. - The company is both the appellant and the appellee in this case, having filed a counterclaim against Hengsheng Pharmaceutical [2][3]. Financial Implications - The original claim amount is 20 million yuan, with a counterclaim of approximately 7.41 million yuan, and the first-instance judgment amounting to about 2.4 million yuan [2]. - The company has proactively made full provisions for bad debts related to accounts receivable and contract assets, indicating that the lawsuit will not negatively impact current or future profits [2][7]. Recent Developments - Following the first-instance judgment, the company has submitted an appeal to the Hunan High People's Court, seeking to overturn the initial ruling and support its counterclaims [5]. - Hengsheng Pharmaceutical has also filed an appeal, requesting the enforcement of a technical development contract and an increase in the compensation amount [6].

Group 1 - The 2025 China-Africa Innovation Cooperation and Development Forum was held in Wuhan, attended by approximately 800 representatives from 43 countries and regions, focusing on innovation and cooperation opportunities [1] - The forum featured 12 parallel sessions, including a project promotion meeting for industrial cooperation between China and African countries, emphasizing areas such as technology innovation, modern agriculture, and health [1] - A total of 39 cooperation agreements were signed during the forum, including the establishment of the China-Africa Photovoltaic Industry Alliance, marking a shift towards ecological collaboration in renewable energy [1] Group 2 - The Jiangxia Laboratory signed a memorandum of cooperation with Tanzania's National Public Health Laboratory to enhance Tanzania's capabilities in pharmaceutical research and infectious disease prevention [2] - The main forum released three significant documents, including the "African Food-Water Resources-Environmental Protection and Development Scientific Action Plan (2026-2030)" and the "African Industrialization Blue Book (2024) - Focus on New Energy Industry" [2]

Group 1 - The core viewpoint of the news is that Bid Pharma has seen a stock price increase of 5.01%, reaching 75.90 CNY per share, with a total market capitalization of 6.898 billion CNY [1] - Bid Pharma focuses on the front end of the new drug research and development industry chain, providing innovative drug molecular building blocks and scientific reagents [1] - The main business revenue composition includes: 43.26% from molecular building block heterocyclic compounds, 23.32% from molecular building block aromatic compounds, 16.36% from molecular building block aliphatic compounds, 10.57% from catalysts and ligands, and 6.49% from life science reagents [1] Group 2 - The Guotou Ruijin Healthcare Mixed A Fund holds 53,200 shares of Bid Pharma, accounting for 2.84% of the fund's net value, ranking as the ninth largest holding [2] - The fund has achieved a year-to-date return of 32.49%, ranking 2279 out of 8136 in its category [2] - The fund manager, Liu Zexu, has a tenure of 2 years and 71 days, with the best fund return during this period being 31.19% [3]

长江商报消息 ●长江商报记者 李璟 又一上市公司总部落地武汉。 11月18日，朗新集团（300682.SZ）在武汉光谷举行武汉总部揭牌仪式，标志着其在武汉的战略布局迈入实质性阶 段，也是"AI+能源"融合创新成果的集中展示。 根据朗新科技官微发布的消息，当天仪式上，朗新集团同步揭牌"朗新九功人工智能实验室"，并发布自主研发 的"电力交易智能体"产品，引发行业广泛关注。未来，公司将在武汉打造人工智能实验室，并研发服务于电力交 易的智能体。 朗新集团董事长徐长军在揭牌仪式上表示，武汉总部的正式启用，标志着公司扎根武汉的战略布局进入全新阶 段。作为AI驱动的领先能源科技企业，朗新集团将以AI技术为核心引擎，全面整合"AI研发、人才培养、业务运 营"三大职能，充分依托武汉东湖高新区在人才集聚、基础设施、产业政策与创新生态方面的优势，加快人工智能 与能源深度融合的技术研发和场景拓展。 激活区域发展新动能 2025年5月，朗新集团携手光谷交通投资集团打造的东湖高新区综合交通管理服务平台正式上线运行，首批纳入19 个停车场的8798个停车位，以及28座公共充电站，车位和充电桩信息可在光谷出行APP和小程序上共享，方便车 主 ...

多只跟踪纳斯达克100指数的QDII发布溢价风险提示 11月19日，富国纳斯达克100ETF、华夏纳斯达克100ETF、华泰柏瑞纳斯达克100ETF等多只跟踪纳斯达 克100指数的QDII发布溢价风险提示公告。公告指出，相关基金的二级市场交易价格明显高于基金份额 参考净值，出现较大幅度溢价，特此提示投资者关注二级市场交易价格溢价风险。 (证券时报) 多家黄金珠宝品牌单克足金饰品价格重回1290元上方 多家黄金珠宝品牌公布的国内足金饰品价格止住跌势，重回1290元/克关口之上。具体而言，11月19 日，周生生足金首饰境内价格为1296元/克，周大福足金（饰品、工艺品类）、谢瑞麟足金饰品、潮宏 基足金（首饰摆件）境内价格为1295元/克，六福珠宝足金999/足金为1293元/克，单克均较前一日上涨7 元。老庙黄金上海区域足金饰品价格为1291元/克，单克较前一日上涨6元。（上证报） 闪存全面大幅涨价 最高涨幅达38.46% 继DRAM大幅涨价后，闪存（Flash）也全面涨价。据CFM闪存市场最新报价，11月19日，Flash Wafer （闪存晶圆）价格全面上涨，最高涨幅38.46%。具体来看，1Tb QLC涨2 ...

Core Viewpoint - The company, Baicheng Pharmaceutical, positions itself as a technology-driven pharmaceutical research and development enterprise, emphasizing innovation and a comprehensive value chain [1] Group 1: Company Overview - Baicheng Pharmaceutical is characterized by its innovative, full-value chain, platform-based, and inclusive attributes [1] - The company has developed an AI platform named "Smart Drug AI," which is applicable for toxicity prediction as well as activity and drug-likeness prediction [1] Group 2: Research and Development Capabilities - The new drug department of the company features an organoid platform that offers drug development technical services, including drug screening, efficacy evaluation, and safety assessment [1]

Core Viewpoint - Baicheng Pharmaceutical (301096.SZ) is a technology-driven pharmaceutical research and development company that integrates innovative, full-value chain, platform-based, and collaborative attributes [1] Group 1 - The company has developed an AI platform called "Smart Drug AI," which can be applied to toxicity prediction as well as activity and drug-likeness prediction [1] - The new drug department features an organoid platform that provides drug research and development technical services, including drug screening, efficacy evaluation, and safety assessment [1]